Novo Nordisk Investor Presentation - First Nine Months of 2016
Investor presentation
First nine months of 2016
Slide 79
More than 20 million people in the US have a BMI above 35
with either pre-diabetes or CV related comorbidities
Incidence of obesity in the US (million people)
Comorbidity
status
BMI
27-29.9
Class I
BMI
30-34.9
Obesity
Class II
BMI
Class III
BMI
Total
35-39.9
40+
No CV
15.5
11.0
4.2
3.0
33.7
comorbidities¹
CV
15.1
16.0
6.4
4.1
41.6
comorbidities²
Pre-diabetes³
12.0
14.1
7.2
6.1
39.4
The US obesity burden
Cost of obesity to health care systems of USD 147 billion
annually with continued growth 5
Around 35% of the US adult population (over 20 years)
have obesity (BMI >30)6
Only around 30% of all obesity cases in the US were
diagnosed in 20097
In 2010, only 3 million people in the US or around 3% of the
adult population with obesity were treated with anti-obesity
medication8
Type 2
diabetes4
2.0
5.0
3.6
2.3
12.9
Total
44.6
46.1
21.4
15.5
127.6
1 Normal blood glucose without hypertension and/or dyslipidemia
2 Normal blood glucose with hypertension and/or dyslipidaemia
3 Impaired Fasting Glucose with or without hypertension and/or dyslipidaemia
4 Type 2 diabetes with or without hypertension and/or dyslipidaemia
Source: 2009-2010 NHANES + revised 2011 CDC estimates and based on US population 2015. Only
includes population age 20+. Distribution between obese groups on market map based on NHANES data
(including only measured and not self reported BMI and also measured not self-reported diabetes status)
5 Finkelstein et al. Health Affairs 28, no. 5 (2009): w822-831
6 Flegal, KM. JAMA. 2012;307(5): Doi: 10.1001/jama.2012.39
7 Ma et al. Obesity (Silver Spring) 2009;17:1077-85
8 Obesity. Decision resources, Inc. December 2010:38
novo nordiskView entire presentation